胰高血糖素样肽-1受体激动剂在神经系统疾病治疗中的研究进展  

Advances of glucagon-like peptide-1 receptor agonists in the treatment of nervous system diseases

作　　者：印蕾[1] 王影[1] 陈松[1] 高向东[1] 

机构地区：[1]中国药科大学生命科学与技术学院,南京210009

出　　处：《中国药科大学学报》2014年第4期383-391,共9页Journal of China Pharmaceutical University

基　　金：国家自然科学基金资助项目(No.81273496;No.81302780);国家高技术研究发展计划(863计划)资助项目(No.2013AA092901)~~

摘　　要：肠促胰素型糖尿病治疗药物胰高血糖素样肽-1(GLP-1)在人体作用广泛,GLP-1受体在人体分布广泛且疗效多样。研究表明,除治疗糖尿病外,GLP-1受体激动剂在中枢和外周神经系统均能发挥良好的神经保护和抗感染作用,显示了良好的应用前景。本文综述了近年来GLP-1受体激动剂在阿尔茨海默病、帕金森病、脑卒中等神经系统疾病中的临床前和临床治疗中的研究进展。The novel incretin-based diabetic drug, glucagon like peptide-1 （GLP-1）, has a range of physiological effects. The widespread distribution of GLP-1 receptors also determines the pleiotropy of GLP-1 receptor agonists. Recent studies suggest that, in addition to anti-diabetic use, GLP-1 receptor agonists exert neuroprotective and anti-inflammatory effects in both central and peripheral nervous systems. Therefore, GLP-1 receptor agonists show great potential as novel preventive or therapeutic agents for neurodegenerative conditions. This article mainly reviews the recent pre-clinical and clinical studies about GLP-1 receptor agonists applied in Alzheimer＇s disease, Parkinson＇s disease, stroke and other neurological diseases.

关 键 词：胰高血糖素样肽-1 胰高血糖素样肽-1受体激动剂 神经系统疾病 研究进展 

分 类 号：R741[医药卫生—神经病学与精神病学]